Moderna, Inc.
MRNA
$125.59
$14.1312.68%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -42.52% | -43.69% | -93.53% | -69.15% | -32.62% |
| Total Other Revenue | -92.00% | -69.67% | -76.61% | -75.89% | -18.48% |
| Total Revenue | -44.71% | -45.57% | -92.76% | -69.30% | -29.50% |
| Cost of Revenue | -25.38% | 77.14% | -10.14% | 22.41% | 95.56% |
| Gross Profit | -75.65% | -208.73% | -157.75% | -101.36% | -65.16% |
| SG&A Expenses | 25.33% | 58.99% | 57.35% | 13.81% | 86.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.95% | 74.84% | -3.95% | 21.15% | 94.56% |
| Operating Income | -99.62% | -272.56% | -176.30% | -108.66% | -70.79% |
| Income Before Tax | -95.77% | -260.89% | -170.70% | -107.21% | -69.41% |
| Income Tax Expenses | -177.37% | 860.92% | -233.21% | -167.13% | -64.94% |
| Earnings from Continuing Operations | -85.19% | -448.03% | -162.81% | -97.84% | -69.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.19% | -448.03% | -162.81% | -97.84% | -69.91% |
| EBIT | -99.62% | -272.56% | -176.30% | -108.66% | -70.79% |
| EBITDA | -87.47% | -237.84% | -170.35% | -106.69% | -69.75% |
| EPS Basic | -85.03% | -456.25% | -165.28% | -97.75% | -68.34% |
| Normalized Basic EPS | -94.39% | -261.05% | -174.16% | -106.64% | -67.79% |
| EPS Diluted | -85.11% | -476.68% | -169.12% | -97.79% | -67.78% |
| Normalized Diluted EPS | -94.31% | -270.13% | -178.47% | -106.71% | -67.41% |
| Average Basic Shares Outstanding | -1.04% | -2.31% | -3.79% | -3.98% | -4.94% |
| Average Diluted Shares Outstanding | -2.47% | -7.52% | -9.07% | -4.93% | -6.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
